Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference
Palvella Therapeutics (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing therapies for rare genetic skin diseases, has announced its participation in the TD Cowen 45th Annual Healthcare Conference.
The company's management team will present on Tuesday, March 4, 2025, at 2:30 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Palvella's website at www.palvellatx.com.
An archived replay of the webcast will remain available for approximately 90 days following the presentation. Palvella specializes in developing novel therapies for serious, rare genetic skin diseases for which there are currently no FDA-approved treatments.
Palvella Therapeutics (Nasdaq: PVLA), una compagnia biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per malattie genetiche rare della pelle, ha annunciato la sua partecipazione alla 45ª Conferenza Sanitaria Annuale TD Cowen.
Il team di gestione dell'azienda presenterà martedì 4 marzo 2025, alle 14:30 ET. Gli investitori e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Eventi e Presentazioni del sito web di Palvella all'indirizzo www.palvellatx.com.
Una registrazione archiviata del webcast sarà disponibile per circa 90 giorni dopo la presentazione. Palvella si specializza nello sviluppo di terapie innovative per gravi malattie genetiche rare della pelle per le quali attualmente non ci sono trattamenti approvati dalla FDA.
Palvella Therapeutics (Nasdaq: PVLA), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias para enfermedades genéticas raras de la piel, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen.
El equipo de gestión de la empresa presentará el martes 4 de marzo de 2025, a las 2:30 p.m. ET. Los inversores y partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Eventos y Presentaciones en el sitio web de Palvella en www.palvellatx.com.
Una repetición archivada del webcast estará disponible durante aproximadamente 90 días después de la presentación. Palvella se especializa en el desarrollo de terapias novedosas para enfermedades genéticas raras de la piel graves para las cuales actualmente no hay tratamientos aprobados por la FDA.
팔벨라 테라퓨틱스 (Nasdaq: PVLA)는 희귀 유전 피부 질환 치료제를 개발하는 임상 단계의 생명공학 회사로, TD 코웬 제45회 연례 헬스케어 컨퍼런스에 참여한다고 발표했습니다.
회사의 경영진은 2025년 3월 4일 화요일 오후 2시 30분 ET에 발표할 예정입니다. 투자자 및 관심 있는 분들은 팔벨라 웹사이트의 이벤트 및 발표 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다: www.palvellatx.com.
웹캐스트의 아카이브 재생은 발표 후 약 90일 동안 이용 가능할 것입니다. 팔벨라는 현재 FDA 승인 치료법이 없는 심각한 희귀 유전 피부 질환을 위한 혁신적인 치료제를 개발하는 데 전문화되어 있습니다.
Palvella Therapeutics (Nasdaq: PVLA), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour des maladies génétiques rares de la peau, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen.
L'équipe de direction de l'entreprise présentera le mardi 4 mars 2025, à 14h30 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Événements et Présentations du site web de Palvella à l'adresse www.palvellatx.com.
Une rediffusion archivée du webinaire sera disponible pendant environ 90 jours après la présentation. Palvella se spécialise dans le développement de thérapies novatrices pour des maladies génétiques rares de la peau graves pour lesquelles il n'existe actuellement aucun traitement approuvé par la FDA.
Palvella Therapeutics (Nasdaq: PVLA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für seltene genetische Hautkrankheiten konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben.
Das Management-Team des Unternehmens wird am Dienstag, den 4. März 2025, um 14:30 Uhr ET präsentieren. Investoren und Interessierte können über den Bereich Veranstaltungen und Präsentationen auf der Website von Palvella auf einen Live-Webcast der Präsentation zugreifen unter www.palvellatx.com.
Eine archivierte Wiederholung des Webcasts wird etwa 90 Tage nach der Präsentation verfügbar sein. Palvella hat sich auf die Entwicklung neuartiger Therapien für schwere, seltene genetische Hautkrankheiten spezialisiert, für die es derzeit keine von der FDA genehmigten Behandlungen gibt.
- Palvella's participation in a major healthcare conference indicates visibility in the investment community
- The company is addressing unmet medical needs in rare genetic skin diseases with no current FDA-approved treatments
- Providing public access to their presentation demonstrates transparency with investors
- Being a Nasdaq-listed company (PVLA) gives them access to capital markets for potential funding
- As a clinical-stage company, Palvella likely has no revenue-generating products yet
- Development of treatments for rare diseases often involves lengthy clinical trials and regulatory processes
- No specific updates on clinical progress or pipeline developments were mentioned in the announcement
- Rare disease drug development typically carries high research costs with smaller potential patient populations
WAYNE, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that its management team will present at the TD Cowen 45th Annual Healthcare Conference on Tuesday March 4, 2025, at 2:30 p.m. ET.
A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare drug disease drug development veterans, Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN
QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
mnanus@trilonadvisors.com
FAQ
When will Palvella Therapeutics (PVLA) present at the TD Cowen Healthcare Conference?
How can investors access Palvella's (PVLA) presentation at the TD Cowen conference?
What therapeutic areas does Palvella Therapeutics (PVLA) focus on?
What is the current development stage of Palvella Therapeutics (PVLA)?
Where is Palvella Therapeutics (PVLA) headquartered?
